肺部吸入给药制剂及临床应用被引量：33

Pulmonary Drug Delivery Products and Clinical Applications

导出

摘要目的:分析和综述肺吸入制剂的分类、现状及其临床用药。方法:收集国内外发表出版的相关论文及专著,对肺部吸入给药的特点及临床药物制剂进行了分析总结。结果与结论:肺部吸入给药是防治哮喘、慢性阻塞性肺病等呼吸道疾病的首选给药方式。常见的吸入给药制剂包括定量吸入气雾剂、干粉吸入剂和雾化吸入剂,所用药物主要为β2受体激动剂、抗胆碱药物、吸入性糖皮质激素及复方药物等。 Objective： To analyze and summarize the category, status and clinical applications of pulmonary delivery drugs. Methods： The articles and books related to the pulmonary drug delivery were searched and studied in order to analyze and summarize its status and clinical uses. Results and Conclusion： Pulmonary drug delivery administration, including metered dose inhalers, dry powder inhalers and nebulizers, has been the first choice for the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary diseases （COPD）. The commonly used inhaled drugs areβ2-agonists, anticholinergic drugs, corticosteroids and combination products.

作者舒宏崔一民侯曙光

机构地区四川普锐特医药科技有限责任公司北京大学第一医院药剂科

出处《临床药物治疗杂志》 2014年第2期18-24,共7页 Clinical Medication Journal

关键词肺部吸入给药定量吸入气雾剂干粉吸入剂雾化吸入剂 Β2受体激动剂抗胆碱药物吸入糖皮质激素剂 Pulmonary drug delivery Metered dose inhaler Dry powder inhaler Nebulizer β2-agonists Anticholinergic drugs Inhaled corticosteroids

分类号 R563 [医药卫生—呼吸系统] R97 [医药卫生—药品]

引文网络
相关文献

参考文献17

1李娅杰,魏农农,邵颖,胡晓敏,赵明,赵德恒.吸入给药的剂型选择和等效性验证[J].中国新药杂志,2008,17(5):433-436. 被引量：8
2陈新梅.肺部给药研究新进展[J].中国现代药物应用,2010,4(1):224-226. 被引量：19
3王勉,朱家壁,汤玥.肺部给药传递系统的研究进展[J].中国新药杂志,2009,18(8):694-698. 被引量：15
4Laube BL, Janssens HM, de Jongh FH, et al. What thepulmonary specialist should know about the new inhalationtherapies. ERS/ISAM task force report [J]. Eur Respir J,2011,37(6):1308-1331.
5金方、侯曙光译,呼吸道药物递送的基本理论与实践[M].北京:化学工业出版社,2011: 222-223.
6Clarke MJ, Bynm J,Taniforth N. Physicochemical factorsgoverning the performance of nedocromil sodium as a powderaerosol[J]. J Pharm Sci, 2000,89(9):1160-1169.
7郑昕,LouiseR,陈昱,等.含福莫特罗的MDI的研究进展[J].国际医药商情,2012,12:28-30.
8武红莉,叶青.联合雾化吸入溴化异丙托品和沙丁胺醇对哮喘和慢性阻塞性肺病患者的肺功能及动脉血气的影响[J].中国临床保健杂志,2009,12(4):352-354. 被引量：17
9Cazzola M, Spina D, Matera MG. The use of bronchodilatorsin stable chronic obstructive pulmonary disease[J]. PulmPharmaco Ther, 1997,10(3):129-144.
10Laforce C, Aunlann J, de Teresa Parrefiol, et al. Sustained 24-hour efficacy of once daily indacaterol(300mug)in patientswith chronic obstructive pulmonary disease: A randomized,crossover study[J]. Pulm Pharmaco Ther, 2011, 24(1):162-168.